- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05076097
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
3. november 2021 opdateret af: Tianjin Medical University Cancer Institute and Hospital
A Prospective Phase II Clinical Study of Orelabrutinib in Combination With Lenalidomide and Rituximab (OLR) in First-line Treatment of Mantle Cell Lymphoma
This is a single-arm, multicenter, open label phase II clinical study to evaluate the efficacy and safety of OLR in the treatment of initially treated mantle cell lymphoma.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Patients initially treated with mantle cell lymphoma were screened for OLR regimen according to study admission criteria.
The study will accept up to 24 cycles of treatment until disease progression or intolerable toxicity occurs and subjects voluntarily withdraw informed consent.
Patients undergoing hematopoietic stem cell transplantation after complete remission may begin stem cell collection after induction therapy for at least 6 months.
Twenty-nine patients are expected to be enrolled
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
29
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Huilai Zhang, PHD
- Telefonnummer: 18622221228
- E-mail: 18526812877@163.com
Undersøgelse Kontakt Backup
- Navn: Yue Fei, Master
- Telefonnummer: 15865928897
- E-mail: feiyue@tmu.edu.cn
Studiesteder
-
-
Tianjin
-
Tianjin, Tianjin, Kina, 300181
- Rekruttering
- Tianjin Medical University Cancer Insititute & Hospital
-
Kontakt:
- Huilai Zhang, PHD
- Telefonnummer: 18622221228
- E-mail: 18526812877@163.com
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 70 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Histopathologically confirmed mantle cell lymphoma with chromosomal translocation. All subjects must provide adequate archived or fresh tumor tissue samples for immunohistochemistry (IHC) testing.
- Age 18-70, both male and female.
- No previous systemic treatment for lymphoma.
- Have at least one measurable lesion. Measurable disease was defined as measurable tumor masses ≥1.5 cm in one or both dimensions and measurable spleen lesions.
- Eastern Oncology Collaboration group physical status score was 0-2.
- Adequate hematological function
- Life expectancy >3 months.
- Have the ability to provide written informed consent and understand and comply with study requirements.
- Ability to adhere to research visit schedules and other protocol requirements
Exclusion Criteria:
- Histology conformed blastolytic mantle cell lymphoma and polymorphic mantle cell lymphoma.
- Patients with current or suspected central nervous system involvement and history of this disease
- Received Bruton's tyrosine kinase inhibitor treatment
- Receive lenalidomide treatment
- Received other anti-tumor treatments
- Major surgery within 4 weeks prior to screening.
- Have a history of other active malignant diseases within 2 years prior to study entry,
- Systemic fungal, bacterial or viral infection with uncontrolled activity
- The following serological states are known for human immunodeficiency virus (HIV) infection or suggest the presence of active hepatitis B or C virus infection
- Clinically serious cardiovascular disease
- A history of severe hemorrhagic disorders, such as hemophilia A, hemophilia B, von willebrand disease, or A history of spontaneous bleeding requiring blood transfusion or other medical intervention.
- A history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the past 12 months.
- A history of major cerebrovascular disease/event, including stroke or intracranial hemorrhage, in the 6 months prior to first administration of the study drug.
- Anticoagulant therapy with warfarin or an equivalent vitamin K antagonist or anticoagulant therapy is required within 7 days of initial use of the study drug.
- Pregnant or lactating women
- Hypersensitivity to any study drug
- The presence of any life-threatening disease, medical condition, or organ system dysfunction that the investigator considers to be likely to affect the safety of the subject or cause risk
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Orelabtutinib in combination of rituximab and lenalidomide(OLR) Arm
Induction phase of mantle cell L lymphoma: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1
|
Induction treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1. 28 days for a cycle.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Complete Response Rate
Tidsramme: At the end of Cycle 6(each cycle is 28 days)
|
The proportion of patients receiving the treatment with complete remission
|
At the end of Cycle 6(each cycle is 28 days)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Objective Response Rate
Tidsramme: Approximately 2 years
|
The proportion of patients with response of PR and CR.
|
Approximately 2 years
|
Time to Response
Tidsramme: Approximately 1 year
|
Measured from the date of initiation of treatment to the time of response
|
Approximately 1 year
|
The Progression Free Survival Rate in 2 Years
Tidsramme: 2 Years
|
The proportion of patients who didn't achieve disease progression or death in 2 years.
|
2 Years
|
The Overall Survival Rate in 2 Years
Tidsramme: 2 Years
|
The proportion of patients who didn't achieve death in 2 years
|
2 Years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Huilai Zhang, PHD, Director of Hematology Department
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- 2020 ASH, poster 2042
- EHA 2020-Abstract S228
- Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015 Sep;90(9):790-5. doi: 10.1002/ajh.24086. Epub 2015 Jul 27.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
30. september 2021
Primær færdiggørelse (Forventet)
15. oktober 2022
Studieafslutning (Forventet)
15. oktober 2023
Datoer for studieregistrering
Først indsendt
30. september 2021
Først indsendt, der opfyldte QC-kriterier
12. oktober 2021
Først opslået (Faktiske)
13. oktober 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
11. november 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
3. november 2021
Sidst verificeret
1. september 2021
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesygdomme
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom
- Lymfom, kappecelle
- Lægemidlers fysiologiske virkninger
- Antirheumatiske midler
- Antineoplastiske midler
- Immunologiske faktorer
- Antineoplastiske midler, immunologiske
- Angiogenese-hæmmere
- Angiogenesemodulerende midler
- Vækststoffer
- Væksthæmmere
- Lenalidomid
- Rituximab
Andre undersøgelses-id-numre
- TS024
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
No individual patient data will be shared with other researchers
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Mantelcellelymfom
-
Universitaire Ziekenhuizen KU LeuvenUkendtLymfom | Hodgkin lymfom | Non-Hodgkin lymfom (follikulært, diffust B-cel lymfom, PTLD og Mantle Cel lymfom)Belgien
-
University of BolognaNovartisUkendtMyeloproliferative lidelser | Hypereosinofilt syndrom | Kronisk eosinofil leukæmi (CEL)Italien
-
AHS Cancer Control AlbertaCross Cancer InstituteAfsluttetOmfattende Stage Small Cel Lung CancerCanada
-
Novartis PharmaceuticalsAfsluttetKronisk myeloid leukæmi (CML) | Philadelphia kromosom positiv akut lymfoblastisk leukæmi (Ph+ ALL) | Andre Glivec/Gleevec-indicerede hæmatologiske lidelser (HES, CEL, MDS/MPN)Den Russiske Føderation
Kliniske forsøg med Orelabrutinib in in combination of rituximab and lenalidomide(OLR)
-
Case Comprehensive Cancer CenterAfsluttetAny Cancer DiagnosisForenede Stater